Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

QR Code

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

Abigail I Nash,1 Ibrahim Turkoz,2 Adam J Savitz,2 Maju Mathews,2 Edward Kim1 1Janssen Scientific Affairs, LLC, Titusville, NJ 08560, USA; 2Janssen Research and Development, LLC, Titusville, NJ 08560, USA Purpose: Long-acting injectable (LAI) antipsychotic paliperidone palmitate 3-month formulation...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Nash AI, Turkoz I, Savitz AJ, Mathews M, Kim E
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2019
Sujets:	long-acting injectable symptomatic remission double-blind treatment Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/3025c88861b842c99e87d7d9337f7271
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
par: Savitz AJ, et autres
Publié: (2017)

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
par: Savitz AJ, et autres
Publié: (2019)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
par: Mathews M, et autres
Publié: (2019)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
par: O'Donnell A, et autres
Publié: (2021)

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
par: Li H, et autres
Publié: (2018)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
par: El Khoury AC, et autres
Publié: (2021)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
par: Zhao JP, et autres
Publié: (2017)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
par: Si T, et autres
Publié: (2019)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
par: Such P, et autres
Publié: (2021)

Is histological remission of ulcerative colitis achievable?
par: Oleg V. Knyazev, et autres
Publié: (2021)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
par: Lopez A, et autres
Publié: (2019)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
par: Mathews M, et autres
Publié: (2018)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
par: Mathews M, et autres
Publié: (2020)

ACHIEVEMENT OF REMISSION AS A MODERN PURPOSE OF ANTIDEPRESSANT THERAPY
par: O. V. Petrunko
Publié: (2014)

Factors of long-term remission formation in patients with alcohol dependence
par: O. V. Petrunko, et autres
Publié: (2017)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
par: Li N, et autres
Publié: (2018)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
par: Sliwa JK, et autres
Publié: (2012)

Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission
par: Mimari Kanazawa, et autres
Publié: (2021)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
par: Emsley R, et autres
Publié: (2017)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
par: Takada R, et autres
Publié: (2018)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
par: Lambert M, et autres
Publié: (2020)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
par: Emsley R, et autres
Publié: (2018)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
par: Li HF, et autres
Publié: (2015)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
par: Chih-Sung Liang, et autres
Publié: (2021)

The Effective Injection Point of the Popliteal Region: A Cadaver Dissection Without Removing the Perineurium
par: Sohn,Youngjoo, et autres
Publié: (2015)

Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study
par: Saragoussi D, et autres
Publié: (2017)

Perceived stress, quality of life, and coping skills among patients with schizophrenia in symptomatic remission
par: Sheikh Shoib, et autres
Publié: (2021)

An Improved and Efficient Micro-payment Scheme
par: Bayyapu,Praneetha R, et autres
Publié: (2009)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
par: Brasso C, et autres
Publié: (2017)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
par: Gopal S, et autres
Publié: (2020)

Duration Mismatch Negativity Predicts Remission in First-Episode Schizophrenia Patients
par: Suguru Nakajima, et autres
Publié: (2021)

Crossover Control Study of the Effect of Personal Care Products Containing Triclosan on the Microbiome
par: Angela C. Poole, et autres
Publié: (2016)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
par: Ohnishi T, et autres
Publié: (2021)

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
par: Srihari Gopal, et autres
Publié: (2017)

ASSOCIATION OF HYPERDIPLOIDY WITH REMISSION STATUS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA AFTER INDUCTION THERAPY
par: Saqib Hussain Korejo, et autres
Publié: (2019)

BILATERAL VARIABILITY OF Q ANGLE IN SYMPTOMATIC UNILATERAL AND SYMPTOMATIC BILATERAL KNEE PAIN IN INDIAN ADULTS OF DECCAN PLATEAU REGION
par: Jyothinath Kothapalli, et autres
Publié: (2021)

Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression
par: Harada E, et autres
Publié: (2016)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
par: Zhang F, et autres
Publié: (2015)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
par: Dhiren Singh, et autres
Publié: (2009)

Alcohol dependence is formed on the background of violations of mental adaptation
par: T. V. Agibalova, et autres
Publié: (2013)